^
Association details:
| Biomarker: | BRAF V600E + MAP2K1 I111S |
|---|---|
| Cancer: | Melanoma |
| Drug: | Tafinlar (dabrafenib) (BRAF inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Preexisting MEK1 Exon 3 Mutations in V600E/KBRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors
Excerpt:
Among 31 patients with BRAF–mutant melanomas treated with either the BRAFi, PLX4032/vemurafenib or GSK2118436/dabrafenib, 5 MEK1 exon 3 mutations (P124S in 4, I111S in 1) were detected in baseline melanoma tumors of 5 distinct patients...Four of 5 patients with BRAF/MEK1 double-mutant baseline melanomas displayed objective responses in the tumors biopsied, and 3 of 5 patients achieved overall partial response...
DOI:
10.1158/2159-8290.CD-12-0022
